Form 4 Janux Therapeutics Inc For: 31 July
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $JANX -20.02% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$JANX last changed hands at $14.54, -20.02% on the session, 59% below its 52-week high of $35.34 and 20% above its low of $12.12 — in the lower part of the range. Over the year it has ranged 192% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $JANX page.
How much coverage it is getting
Nothing else on $JANX in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$JANX earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $JANX page has the full chart, the filings and the valuation model these figures come from. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $JANX is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $JANX. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 1, 2026. $JANX has moved -5.09% ($15.32 to $14.54). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.